Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Tofacitinib: In the real-world settings, patients with AA treated with tofacitinib.

Baricitinib: In the real-world settings, patients with AA treated with Baricitinib.

Ruxolitinib: In the real-world settings, patients with AA treated with Ruxolitinib.

Upadacitinib: In the real-world settings, patients with AA treated with Upadacitinib.

Abrocitinib: In the real-world settings, patients with AA treated with Abrocitinib.

Ritlecitinib: In the real-world settings, patients with AA treated with Ritlecitinib.

Study summary

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Eligibility

Primary outcome measure(s)

• Mean SALT — at week 24
  Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
• SALT50 — at week 24
  Percentage of patient with more than 50% improvement in SALT score
• SALT75 — at week 24
  Percentage of patient with more than 70% improvement in SALT score

Trial sites (1)

On this site

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition